Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPDD 00031705 is a negative control for PDD 00017238 (Cat. No. 7007).
M. Wt | 490.62 |
Formula | C20H22N6O3S3 |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 2032096-45-8 |
PubChem ID | 123131658 |
InChI Key | KWGUETFSHQZXMA-UHFFFAOYSA-N |
Smiles | CN(S(=O)(C1=CC=C2N(C(N(C2=C1)C3=NC=NS3)=O)CC4=C(N=C(S4)C)C)=O)C5(CC5)C |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
James et al (2016) First-in-class chemical probes against poly(ADP-ribose) glycohydrolase (PARG) inhibit DNA repair with differential pharmacology to Olaparib. ACS Chem.Biol. 11 3179 PMID: 27689388
Keywords: PDD 00031705, PDD 00031705 supplier, PDD00031705, poly, ADP, ribose, glycohydrolase, PARG, inhibitors, negative, controls, Poly(ADP)-ribose, Glycohydrolase, 7009, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for PDD 00031705 include:
Craig A et al (2018) Hypoxia induces pulmonary fibroblast proliferation through NFAT signaling. Sci Rep 8 2709 PMID: 29426911
There are currently no reviews for this product. Be the first to review PDD 00031705 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.